Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.

Stem cells (Dayton, Ohio) - 1 Nov 2012

Hamasaki Makoto, Hashizume Yoshinobu, Yamada Yoshinori, Katayama Tomohiko, Hohjoh Hirohiko, Fusaki Noemi, Nakashima Yasuharu, Furuya Hirokazu, Haga Nobuhiko, Takami Yoichiro, Era Takumi

Abstract excerpt

Fibrodysplasia ossificans progressiva (FOP) is a rare congenital disorder characterized by progressive ossification of soft tissues. FOP is caused by mutations in activin receptor-like kinase 2 (ALK2) that cause its constitutive activation and result in dysregulation of BMP signaling. Here, we sh...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type I
Share to Cell Lineage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coculture Techniques

Share to Drug Evaluation, Preclinical

Share to Induced Pluripotent Stem Cells

Share to Myositis Ossificans

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 22949078
DOI: 10.1002/stem.1221

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22949078-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.PMID 22949078Read ↗

Concurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC.Semantic proximity Read ↗

Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

From mysteries to medicines: drug development for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Multi-omics reveals global signaling rewiring and identifies Activin A-induced dysregulation of FOS/Activator Protein 1 as a novel target in Fibrodysplasia ossificans progressivaSemantic proximity Read ↗

Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting.Semantic proximity Read ↗

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.Semantic proximity Read ↗

Recent progress in drug development for fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.